In vitro cytotoxicity of ranpirnase (onconase) in combination with components of R-CHOP regimen against diffuse large B cell lymphoma (DLBCL) cell line

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 67, Issue , 2013, Pages 1166-1172

  Majchrzak, Agata ^a   Witkowska, Magdalena ^a   Mȩdra, Aleksandra ^a   Zwolińska, Małgorzata ^a   Bogusz, Jakub ^a   Cebula Obrzut, Barbara ^a   Darzynkiewicz, Zbigniew ^b   Robak, Tadeusz ^a   Smolewski, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Diffuse large B cell lymphoma; DLBCL; Onconase; R CHOP regimen; Toledo cell line

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; R CHOP PROTOCOL; R-CHOP PROTOCOL; RANPIRNASE; RIBONUCLEASE; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL LINE; DRUG EFFECT; HUMAN; LARGE CELL LYMPHOMA; TREATMENT OUTCOME;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDNISONE; RIBONUCLEASES; TREATMENT OUTCOME; VINCRISTINE;

EID: 84892579139     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1078386     Document Type: Article

References (34)

1. Ardelt B., Ardelt W., Darzynkiewicz Z.: Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle, 2003;2:22-24
2. Ardelt B., Juan G., Burfeind P., Salomon T., Wu J. M., Hsieh T. C., Li X., Sperry R., Pozarowski P., Shogen K., Ardelt W., Darzynkiewicz Z.: Onconase, an anti-tumor ribonuclease suppresses intracellular oxidative stress. Int. J. Oncol., 2007;31:663-669
3. Basseres D. S., Baldwin A. S.: Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene, 2006;30:6817-6830
4. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P., Gisselbrecht C.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med., 2002;346:235-242
5. D'Alessio G., Di Donato A., Mazzarella L., et al.: Seminal ribonuclease: the importance of diversity. In: D'Alessio G., Riordan J. F., editors. Ribonucleases: structures and functions. New York, NY, USA: Academic Press, 1997;383-423
6. Darzynkiewicz Z., Carter S. P., Mikulski S. M., Ardelt W., Shogen K.: Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet., 1988;21:169-182
7. Deptala A., Halicka H. D., Ardelt B., Ardelt W., Mikulski S. M., Shogen K., Darzynkiewicz Z.: Potentiation of tumor necrosis factor induced apoptosis by onconase. Int. J. Oncol., 1998;13:11-16
8. Dyer K. D., Rosenberg H. F.: The RNase A superfamily: generation of diversity and innate host defense. Mol. Divers., 2006;10:585-597
9. Fredman P.: Glycosphingolipid tumor antigens. Adv. Lipid Res., 1993;25:213-234
10. Goparaju C. M., Blasberg J. D., Volinia S., Palatini J., Ivanov S., Donington J. S., Croce C., Carbone M., Yang H., Pass H. I.: Onconase mediated NFKβ downregulation in malignant pleural mesothelioma. Oncogene, 2011;16:2767-2777
11. Grabarek J., Ardelt B., Du L., Darzynkiewicz Z.: Activation of caspases and serine proteases during apoptosis induced by onconase (ranpirnase). Exp. Cell Res., 2002;278:61-71
12. Halicka H. D., Murakami T., Papageorgio C. N., Mittelman A., Mikulski S. M., Shogen K., Darzynkiewicz Z.: Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by onconase. Cell Prolif., 2000;33:407-417
13. Iordanov M. S., Ryabinina O. P., Wong J., Dinh T. H., Newton D. L., Rybak S. M., Magun B. E.: Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: Evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res., 2000;60:1983-1994
14. Ita M., Halicka H. D., Tanaka T., Kurose A., Ardelt B., Shogen K., Darzynkiewicz Z.: Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines. Cancer Biol. Ther., 2008;7:1104-1108
15. James A. M., Ambrose E. J., Lowick J. H.: Differences between the electrical charge carried by normal and homologous tumour cells. Nature, 1956;177:576-577
16. Lee I., Kim D. H., Sunar U., Magnitsky S., Shogen K.: The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer. In Vivo, 2007;21:721-728
17. Leland P. A., Raines R. T.: Cancer chemotherapy - ribonucleases to the rescue. Chem. Biol., 2001;8:405-413
18. Leland P. A., Schultz L. W., Kim B. M., Raines R. T.: Ribonuclease A variants with potent cytotoxic activity. Proc. Natl. Acad. Sci. USA, 1998;95:10407-10412
19. Mikulski S., Chun H., Mittelman A., Panella T., Puccio C., Shogen K., Costanzi J.: Relationship between response rate and median survival in patients with advanced nonsmall cell lung-cancer - comparison of onconase (r) with other anticancer agents. Int. J. Oncol., 1995;6:889-897
20. Mikulski S., Grossman A., Carter P., Shogen K., Costanzi J.: Phase-I human clinical-trial of onconase (r) (p-30 protein) administered intravenously on a weekly schedule in cancer-patients with solid tumors. Int. J. Oncol., 1993;3:57-64
21. Mikulski S. M., Viera A., Ardelt W., Menduke H., Shogen K.: Tamoxifen and trifluoroperazine (stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing antitumor activity. Cell Tissue Kinet., 1990;23:237-246
22. Mikulski S. M., Viera A., Darzynkiewicz Z., Shogen K.: Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. Br. J. Cancer, 1992;66:304-310
23. Newton D. L., Hansen H. J., Mikulski S. M., Goldenberg D. M., Rybak S. M.: Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood, 2001;97:528-535
24. Riordan J. F.: Structure and function of angiogenin. In: D'Alessio G., Riordan J. F., editors. Ribonucleases: structures and functions. New York, NY, USA: Academic Press, 1997;445-489
25. Rutkoski T. J., Raines R. T.: Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. Curr. Pharm. Biotechnol., 2008;9:185-189
26. Rybak S. M., Pearson J. W., Fogler W. E., Volker K., Spence S. E., Newton D. L., Mikulski S. M., Ardelt W., Riggs C. W., Kung H. F., Longo D. L.: Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. J. Natl. Cancer Inst., 1996;88:747-753
27. Sawczuk-Chabin J., Centkowski P., Bilinski P., Warzocha K.: Epidemiologia nieziarniczych chłoniaków złośliwych. Acta Haematol. Pol., 2004;35:131-144
28. Shogen K., Yoan W. K.: Antitumor activity in extracts of leopard frog (Rana pipiens) embryos. 27th Annual Eastern Colleges Science Conference; The Pennsylvania State University, State College, 1973
29. Takahashi M., Chiyo T., Okada T., Hohjoh H.: Specific inhibition of tumor cells by oncogenic EGFR specific silencing by RNA interference. PLoS One, 2013;8:e73214
30. Tang C. H., Hu C. C., Wei C. W., Wang J. J.: Synergism of Rana catesbeiana ribonuclease and IFN-γ triggers distinct death machineries in different human cancer cells. FEBS Lett., 2005;579:265-270
31. Tsai S. Y., Ardelt B., Hsieh T. C., Darzynkiewicz Z., Shogen K., Wu J. M.: Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-κB. Int. J. Oncol., 2004;25:1745-1752
32. Turcotte R. F., Lavis L. D., Raines R. T.: Onconase cytotoxicity relies on the distribution of its positive charge. FEBS J., 2009;276:3846-3857
33. Vasandani V. M., Castelli J. C., Hott J. S., Saxena S., Mikulski S. M., Youle R. J.: Interferon enhances the activity of the anticancer ribonuclease, onconase. J. Interferon Cytokine Res., 1999;19:447-454
34. Zhao H., Ardelt B., Ardelt W., Shogen K., Darzynkiewicz Z.: The cytotoxic ribonuclease onconase targets RNAi (siRNA). Cell Cycle, 2008;7:3258-3261